• Gentium SpA, of Villa Guardia, Italy, said it submitted its responses to the Day 180 list of outstanding issues received from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy.